Remove Doctors Remove Insulin Remove Production
article thumbnail

World Diabetes Day 2024: Advanced Care for Diabetes Management

XTalks

Cure Research: Moving Toward an Insulin-Free Future JDRF is focused on funding research that is accelerating the development of new treatments for people with T1D — for all ages and stages. “Our before people need insulin therapy), so that it’s possible to intervene with therapies that can stop clinical disease before it starts.”

Insulin 108
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications.

Drugs 295
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

As we’ve seen over those five years, biosimilars are critical in continuing to provide doctors and patients choice in their care plans as well as continuing to decrease overall healthcare costs. One of these markets is the insulin market. Americans pay ten times as much for insulin as Canadian patients do.

Marketing 119
article thumbnail

MIOTIFY platform for digital health products clears AZ road test

pharmaphorum

UK company MIOTIFY has developed a web-based software platform that product teams can use to configure medical algorithms quickly, create code packages to harness them and generate supporting documentation – all in a format that is designed to meet regulatory requirements for software as a medical device (SaMD). .

article thumbnail

Medtronic Introduces New Minimed 770G For Type 1 Diabetes

XTalks

This is an insulin pump system that offers the company’s most advanced SmartGuard technology. Furthermore, the notices can also be automatically shared with clinicians and educators to help facilitate more effective telehealth visits and product trainings. ” The pancreas of people with type 1 diabetes cannot produce insulin.

Insulin 98
article thumbnail

Health2Sync and Sanofi to digitally manage diabetes in Taiwan

pharmaphorum

While Sanofi is winding up its R&D operations in diabetes it is turning to digital solutions to get the most from its established products for the disease. But use of insulin is relatively low compared with American and European countries and there are an estimated 2.2 million diabetes patients in Taiwan.

Insulin 76
article thumbnail

Sanofi extends Health2Sync digital diabetes partnership to Japan

pharmaphorum

Digital health company Health2Sync will work with Sanofi on digitising its range of insulin products in Japan, extending an earlier alliance in other markets. The new Japanese alliance will however go a step further. “Patients are receiving an average of 14.8 “Patients are receiving an average of 14.8

Insulin 52